Lower Mortality Risk Associated With Remdesivir + Dexamethasone Versus Dexamethasone Alone for the Treatment of Patients Hospitalized for COVID-19
Remdesivir + dexamethasone was associated with a significant reduction in 14- and 28-day mortality compared to dexamethasone alone in patients hospitalized for COVID-19 across all levels of baseline respiratory support, including IMV/ECMO. However, the use of remdesivir + dexamethasone still has low clinical practice uptake. In addition, these data suggest a need to update the existing guidelines.
Authors
- Paul E. Sax (ORCID: https://orcid.org/0000-0001-8434-174X)
- Robert Gottlieb (ORCID: https://orcid.org/0000-0001-8376-8709)
- Chidinma Chima-Melton (ORCID: https://orcid.org/0000-0003-0730-9871)
- Alpesh Amin (ORCID: https://orcid.org/0000-0002-9790-0245)
- Essy Mozaffari
- Tobias Welte (ORCID: https://orcid.org/0000-0002-9947-7356)
- Thomas F Oppelt (ORCID: https://orcid.org/0000-0003-2865-9854)
- André C. Kalil (ORCID: https://orcid.org/0000-0002-6489-6294)
- Aastha Chandak (ORCID: https://orcid.org/0000-0001-5653-435X)
- Jason F. Okulicz (ORCID: https://orcid.org/0000-0002-2704-7162)
- Mark Berry (ORCID: https://orcid.org/0000-0002-8534-2012)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- University of California, Irvine (US)
- Baylor University Medical Center (US)
- Medizinische Hochschule Hannover (DE)
- Baylor Medical Center at Garland (US)
- Heart Hospital Baylor Plano (US)
- Certara (United States) (US)
- Gilead Sciences (United States) (US)
- Baylor Jack and Jane Hamilton Heart and Vascular Hospital (US)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1093/cid/ciae477
- Citations
- 13
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.06
Funders
- Gilead Sciences